Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
First Step With Singulair® Therapy (0476-323)
Phase 4
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 399
- Registration Number
- NCT00545324
Singulair(R) In Asthma And Allergic Rhinitis (0476-383)
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 313
- Registration Number
- NCT00545844
Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)
Phase 3
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 516
- Registration Number
- NCT00542087
Health Assessment Study (0954-946)
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 143
- Registration Number
- NCT00541684
Eze/Simva Switch Study in Diabetics (0653A-807)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 648
- Registration Number
- NCT00541697
A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)
Phase 3
Withdrawn
- Conditions
- Asthma, Bronchial
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT00540839
Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)
Phase 4
Completed
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 314
- Registration Number
- NCT00536380
A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1289
- Registration Number
- NCT00535405
The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)
Phase 4
Completed
- Conditions
- Exercise-induced Bronchoconstriction (EIB)
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 364
- Registration Number
- NCT00534976
A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828)
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Drug: Mometasone furoate dry powder inhalerDrug: Placebo
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 672
- Registration Number
- NCT00521599
© Copyright 2025. All Rights Reserved by MedPath